Evidence map›Paper›PMID 31678957›Full record

ArticleBMJ open2019

A randomised controlled trial of a case management approach to encourage participation in colorectal cancer screening for people with schizophrenia in psychiatric outpatient clinics: study protocol for the J-SUPPORT 1901 (ACCESS) study.

Masaki Fujiwara, Masatoshi Inagaki, Taichi Shimazu, Masafumi Kodama, Ryuhei So, Takanori Matsushita, Yusaku Yoshimura, Shigeo Horii, Maiko Fujimori, Hirokazu Takahashi and 8 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Masaki FujiwaraDepartment of Neuropsychiatry, Okayama University Hospital, Okayama, Japan.
Masatoshi InagakiDepartment of Psychiatry, Faculty of Medicine, Shimane University, Izumo, Japan minagaki@med.shimane-u.ac.jp.ORCID 0000-0002-9822-8649
Taichi ShimazuDivision of Prevention, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.ORCID 0000-0001-6000-9830
Masafumi KodamaOkayama Psychiatric Medical Center, Okayama, Japan.
Ryuhei SoOkayama Psychiatric Medical Center, Okayama, Japan.
Takanori MatsushitaZikei Hospital, Okayama, Japan.
Yusaku YoshimuraZikei Hospital, Okayama, Japan.
Shigeo HoriiZikei Hospital, Okayama, Japan.
Maiko FujimoriDivision of Health Care Research, Behavioral Sciences and Survivorship Research Group and Division of Cohort Consortium Research, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Hirokazu TakahashiDivision of Screening Assessment and Management, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Naoki NakayaDepartment of Health Sciences, Saitama Prefectural University, Koshigaya, Japan.
Kyoko KakedaDepartment of Neuropsychiatry, Kochi Medical School, Kochi University, Nankoku, Japan.
Tempei MiyajiDepartment of Clinical Trial Data Management, Tokyo University Graduate School of Medicine, Tokyo, Japan.
Shiro HinotsuDepartment of Biostatistics, Sapporo Medical University, Sapporo, Japan.
Keita HaradaDepartment of Gastroenterology, Okayama University Hospital, Okayama, Japan.
Hiroyuki OkadaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yosuke UchitomiInnovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital and Behavioral Sciences and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Norihito YamadaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Okayama Psychiatric Medical Center · JPOkayama University · JPOkayama University Hospital · JPJapan Clinical Cancer Research Organization · JPKōchi University · JPSaitama Prefectural University · JPSapporo Medical University · JPShimane University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOne of the reasons for the high mortality rate from cancer in people with schizophrenia is delay in diagnosis. Many studies have shown lower cancer screening rates in people with schizophrenia; however, there are no interventions for people with schizophrenia to increase cancer screening. Therefore, we developed a case management (CM) intervention to encourage participation in cancer screening. The purpose of this study was to examine the efficacy of CM to encourage participation in cancer screening for people with schizophrenia, with particular focus on colorectal cancer screening by faecal occult blood testing, compared with usual intervention (UI), namely, municipal public education. METHODS AND ANALYSIS: This is an individually randomised, parallel group trial with blinded outcome assessments. The participants will be randomly allocated to either the CM plus UI group or UI alone group in a 1:1 ratio using a web-based program at a data management centre. The primary end point of the study is participation in colorectal cancer screening in the year of intervention, which will be assessed based on municipal records. ETHICS AND DISSEMINATION: This study is performed in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan's Ministry of Education, Science, and Technology and the Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information as well as the Declaration of Helsinki. This study was approved by the institutional ethics committee at the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital on 23 April 2019 (approval number: RIN1904-003). The findings of this trial will be submitted to an international peer-reviewed journal. TRIAL REGISTRATION NUMBER: UMIN000036017.

Indexed as

Case ManagementEarly Detection of CancerPatient ParticipationColorectal NeoplasmsHumansRandomized Controlled Trials as TopicSchizophreniacancer screeningcase managementdisabilityearly detection of cancerschizophreniasevere mental illness

Identifiers

PMID31678957
PMCPMC6830660
OpenAlexW2983506068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.